We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




PARP-Inhibitors Reduce Damage in Some Neurological Disorders

By LabMedica International staff writers
Posted on 20 Aug 2018
A recent study found that blocking the activity of the poly(ADP-ribose)polymerase (PARP) family of enzymes reduced the amount of harmful TDP-43 (transactive response DNA binding protein) structures in brain cells under stress and slowed or prevented development of cytoplasmic inclusions found in neurological disorders such as amyotrophic lateral sclerosis (ALS), and some forms of frontotemporal degeneration (FTD).

In ALS and FTD, cytoplasmic aggregates of hyperphosphorylated TDP-43 accumulate and co-localize with some stress granule components, but how pathological TDP-43 aggregation is transferred to the nucleus remains unknown.

Investigators at the University of Pennsylvania (Philadelphia, USA) used cell cultures and a Drosophila (fruit fly) model to show that downregulation of the enzyme tankyrase, a PAR polymerase, reducedTDP-43 accumulation in the cytoplasm and potently inhibited neurodegeneration. More...
They established that TDP-43 non-covalently bound to PAR via PAR-binding motifs embedded within its nuclear localization sequence. PAR binding promoted liquid-liquid phase separation of TDP-43 in vitro and was required for TDP-43 accumulation in stress granules in mammalian cells and neurons. Stress granule localization initially protected TDP-43 from disease-associated phosphorylation, but upon long-term stress, stress granules eventually dissolved, leaving behind aggregates of phosphorylated TDP-43.

The investigators reported in the August 9, 2018, online edition of the journal Molecular Cell that PARP inhibitors, which stop PAR from being generated, reduced the amount of harmful TDP-43 structures localized into stress granules. This reduced TDP-43-linked pathology and neurodegeneration and could be of use therapeutically for the treatment of ALS and FTD.

“Given the lack of treatment options, we are excited by these experiments that help elucidate molecular events that could lead to new therapeutics,” said senior author Dr. Nancy Bonini, professor of biology at the University of Pennsylvania.

Related Links:
University of Pennsylvania


Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Pan-Cancer Panel
TruSight Oncology 500
New
Anti-Thyroid Peroxidase Assay
LIAISON Anti-TPO
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more

Pathology

view channel
These images illustrate how precision oncology Organ Chips recapitulate individual patients’ responses to chemotherapy (Photo courtesy of Wyss Institute at Harvard University)

Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response

Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.